Cargando…

Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma

BACKGROUND: Thyroid carcinoma is a common endocrine tumor in the dog. Local invasive growth frequently precludes surgical excision and, in up to 38% of dogs, the tumor has already metastasized by the time of diagnosis. Therefore, it is important to investigate new treatment modalities that may be us...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos, M., Ducatelle, R., Kooistra, H.S., Rutteman, G., Duchateau, L., Polis, I., Daminet, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857974/
https://www.ncbi.nlm.nih.gov/pubmed/24612088
http://dx.doi.org/10.1111/jvim.12330
_version_ 1782430724694999040
author Campos, M.
Ducatelle, R.
Kooistra, H.S.
Rutteman, G.
Duchateau, L.
Polis, I.
Daminet, S.
author_facet Campos, M.
Ducatelle, R.
Kooistra, H.S.
Rutteman, G.
Duchateau, L.
Polis, I.
Daminet, S.
author_sort Campos, M.
collection PubMed
description BACKGROUND: Thyroid carcinoma is a common endocrine tumor in the dog. Local invasive growth frequently precludes surgical excision and, in up to 38% of dogs, the tumor has already metastasized by the time of diagnosis. Therefore, it is important to investigate new treatment modalities that may be useful for the large number of dogs with inoperable tumors or metastatic disease. HYPOTHESIS/OBJECTIVES: To investigate the immunohistochemical expression of potential therapeutic targets in canine thyroid tumors. ANIMALS: 74 dogs with thyroid neoplasia. METHODS: Immunohistochemistry was performed for thyroglobulin, calcitonin, vascular endothelial growth factor (VEGF), p53, cycloxygenase‐2 (cox‐2), and P‐glycoprotein (P‐gp). RESULTS: Fifty‐four (73%) tumors were classified as follicular cell thyroid carcinomas (FTCs) and 20 (27%) as medullary thyroid carcinomas (MTCs). Eighty percent of FTCs and all MTCs had a high percentage (76–100%) of neoplastic cells immunopositive for VEGF. Thirteen percent of FTCs and 50% of MTCs expressed cox‐2. Seven percent of FTCs and 70% of MTCs expressed P‐gp. No tumor was immunopositive for p53 expression. Expression of VEGF (P = .034), cox‐2 (P = .013), and P‐gp (P < .001) was significantly higher in MTCs compared to FTCs. CONCLUSIONS AND CLINICAL IMPORTANCE: VEGF is a potential therapeutic target in both FTC and MTC in dogs. Cox‐2 and P‐gp may be useful molecular targets in canine MTC.
format Online
Article
Text
id pubmed-4857974
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48579742016-06-22 Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma Campos, M. Ducatelle, R. Kooistra, H.S. Rutteman, G. Duchateau, L. Polis, I. Daminet, S. J Vet Intern Med Standard Articles BACKGROUND: Thyroid carcinoma is a common endocrine tumor in the dog. Local invasive growth frequently precludes surgical excision and, in up to 38% of dogs, the tumor has already metastasized by the time of diagnosis. Therefore, it is important to investigate new treatment modalities that may be useful for the large number of dogs with inoperable tumors or metastatic disease. HYPOTHESIS/OBJECTIVES: To investigate the immunohistochemical expression of potential therapeutic targets in canine thyroid tumors. ANIMALS: 74 dogs with thyroid neoplasia. METHODS: Immunohistochemistry was performed for thyroglobulin, calcitonin, vascular endothelial growth factor (VEGF), p53, cycloxygenase‐2 (cox‐2), and P‐glycoprotein (P‐gp). RESULTS: Fifty‐four (73%) tumors were classified as follicular cell thyroid carcinomas (FTCs) and 20 (27%) as medullary thyroid carcinomas (MTCs). Eighty percent of FTCs and all MTCs had a high percentage (76–100%) of neoplastic cells immunopositive for VEGF. Thirteen percent of FTCs and 50% of MTCs expressed cox‐2. Seven percent of FTCs and 70% of MTCs expressed P‐gp. No tumor was immunopositive for p53 expression. Expression of VEGF (P = .034), cox‐2 (P = .013), and P‐gp (P < .001) was significantly higher in MTCs compared to FTCs. CONCLUSIONS AND CLINICAL IMPORTANCE: VEGF is a potential therapeutic target in both FTC and MTC in dogs. Cox‐2 and P‐gp may be useful molecular targets in canine MTC. John Wiley and Sons Inc. 2014-02-24 2014 /pmc/articles/PMC4857974/ /pubmed/24612088 http://dx.doi.org/10.1111/jvim.12330 Text en Copyright © 2014 by the American College of Veterinary Internal Medicine
spellingShingle Standard Articles
Campos, M.
Ducatelle, R.
Kooistra, H.S.
Rutteman, G.
Duchateau, L.
Polis, I.
Daminet, S.
Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma
title Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma
title_full Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma
title_fullStr Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma
title_full_unstemmed Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma
title_short Immunohistochemical Expression of Potential Therapeutic Targets in Canine Thyroid Carcinoma
title_sort immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma
topic Standard Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857974/
https://www.ncbi.nlm.nih.gov/pubmed/24612088
http://dx.doi.org/10.1111/jvim.12330
work_keys_str_mv AT camposm immunohistochemicalexpressionofpotentialtherapeutictargetsincaninethyroidcarcinoma
AT ducateller immunohistochemicalexpressionofpotentialtherapeutictargetsincaninethyroidcarcinoma
AT kooistrahs immunohistochemicalexpressionofpotentialtherapeutictargetsincaninethyroidcarcinoma
AT ruttemang immunohistochemicalexpressionofpotentialtherapeutictargetsincaninethyroidcarcinoma
AT duchateaul immunohistochemicalexpressionofpotentialtherapeutictargetsincaninethyroidcarcinoma
AT polisi immunohistochemicalexpressionofpotentialtherapeutictargetsincaninethyroidcarcinoma
AT daminets immunohistochemicalexpressionofpotentialtherapeutictargetsincaninethyroidcarcinoma